Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Cyclopharm Limited is expanding its ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Cyclopharm Limited’s Technegas ...

Jubilant Life Sciences subsidiary Jubilant DraxImage Inc has signed a deal with Australia's Cyclopharm to market Technegas, an imaging agent primarily used in ...

Jubilant Life Sciences said its subsidiary Jubilant DraxImage Inc has signed a term sheet with Cyclopharm for licence to market Technegas in the US. Technegas is an imaging agent primarily used in ...

After a long and bumpy path to approval, the U.S. FDA has finally given the green light to Cyclopharm Ltd.'s Technegas combination product a day after the Sept. 29 PDUFA date. Technegas is a nuclear ...

Shares of Jubilant Life Sciences gained nearly 4 percent intraday Monday after its susbidiary signed term sheet to market Technegas in the US. "Wholly-owned subsidiary Jubilant DraxImage Inc has ...

Cyclopharm is eyeing new indications for its Technegas device, notably asthma detection The company says its fledgling US business is close to profitability Technegas has been used since the 1980s, ...

Cyclopharm Chief Executive James McBrayer says Technegas is an “Australian innovation” in the lung function space. “Technegas is a very unique product, it’s an Australian innovation,” Mr McBrayer told ...

PERTH, Australia – Cyclopharm Ltd. said it received a complete response letter (CRL) from the FDA for its Technegas NDA for pulmonary embolisms. The CRL relates to better defining and validating ...

Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and execution of the Definitive ...

New Delhi: Jubilant Life Sciences today said its wholly-owned subsidiary and Australia-based Cyclopharm have mutually called off their previously announced term sheet for exclusive commercial rights ...